# A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05888831/  
OnCo record `nct05888831` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05888831 by Bristol-Myers Squibb, with 100 participants enrolled, started 2023-06-06 and due to reach its primary completion in 2026-09-30. Interventions recorded: BMS-986449 and Nivolumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05888831
- Phase: 1/2
- Setting: A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors
- Sponsor: Bristol-Myers Squibb
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05888831: https://clinicaltrials.gov/study/NCT05888831

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct05888831.json